Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.

Koussounadis A, Langdon SP, Harrison DJ, Smith VA.

Br J Cancer. 2014 Jun 10;110(12):2975-84. doi: 10.1038/bjc.2014.258. Epub 2014 May 27.

2.

An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.

Janzen DM, Tiourin E, Salehi JA, Paik DY, Lu J, Pellegrini M, Memarzadeh S.

Nat Commun. 2015 Aug 3;6:7956. doi: 10.1038/ncomms8956.

3.

Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.

Munk Jensen M, Erichsen KD, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

PLoS One. 2013 Dec 26;8(12):e85126. doi: 10.1371/journal.pone.0085126. eCollection 2013.

4.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

5.

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.

Koussounadis A, Langdon SP, Um I, Kay C, Francis KE, Harrison DJ, Smith VA.

BMC Cancer. 2016 Mar 10;16(1):205. doi: 10.1186/s12885-016-2212-6.

6.

Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.

Wang H, Zhu L, Gao J, Hu Z, Lin B.

Oncol Rep. 2015 Jan;33(1):403-12. doi: 10.3892/or.2014.3549. Epub 2014 Oct 17.

PMID:
25354091
8.

Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.

Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK.

PLoS One. 2012;7(2):e30550. doi: 10.1371/journal.pone.0030550. Epub 2012 Feb 10.

9.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
10.

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.

Clin Cancer Res. 2005 Aug 15;11(16):6030-9.

11.

Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.

Horio M, Kato T, Mii S, Enomoto A, Asai M, Asai N, Murakumo Y, Shibata K, Kikkawa F, Takahashi M.

Cancer Med. 2012 Oct;1(2):218-29. doi: 10.1002/cam4.32. Epub 2012 Sep 13.

12.

Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.

Tong L, Chen W, Wu J, Li H.

Anticancer Drugs. 2014 Mar;25(3):244-54. doi: 10.1097/CAD.0000000000000047.

PMID:
24275314
13.

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.

Clin Cancer Res. 2007 Dec 1;13(23):7191-8.

14.

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.

Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N.

BMC Cancer. 2014 May 6;14:317. doi: 10.1186/1471-2407-14-317.

15.

Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.

Ricciardelli C, Ween MP, Lokman NA, Tan IA, Pyragius CE, Oehler MK.

BMC Cancer. 2013 Oct 14;13:476. doi: 10.1186/1471-2407-13-476.

16.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.

Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. Lancet Oncol. 2015 Feb;16(2):e55.

PMID:
25481791
17.

High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.

Osterberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G.

Cytogenet Genome Res. 2009;125(1):8-18. doi: 10.1159/000218744. Epub 2009 Jul 14.

PMID:
19617691
18.

[Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].

Zhang SL, Jiang T, Lin B, Zhao CQ, Meng LR.

Zhonghua Fu Chan Ke Za Zhi. 2004 Jul;39(7):482-5. Chinese.

PMID:
15347474
19.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
20.

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.

Pénzváltó Z, Lánczky A, Lénárt J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I, Győrffy B.

BMC Cancer. 2014 Nov 18;14:837. doi: 10.1186/1471-2407-14-837.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk